LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Several other brokerages have also recently issued reports on LMAT. JMP Securities upped their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Barrington Research increased their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Roth Mkm reissued a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a research report on Friday, May 31st. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their price objective for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $77.57.

LeMaitre Vascular Stock Down 0.5 %

Shares of LMAT stock opened at $85.83 on Thursday. The stock has a market cap of $1.93 billion, a P/E ratio of 56.84, a PEG ratio of 2.75 and a beta of 0.89. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $91.76. The company’s fifty day simple moving average is $81.97 and its two-hundred day simple moving average is $70.60.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.27 EPS. On average, analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now directly owns 2,133,428 shares in the company, valued at $161,500,499.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The disclosure for this sale can be found here. Insiders sold a total of 127,437 shares of company stock worth $10,076,242 over the last three months. Corporate insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Conestoga Capital Advisors LLC raised its position in shares of LeMaitre Vascular by 0.4% in the second quarter. Conestoga Capital Advisors LLC now owns 1,941,501 shares of the medical instruments supplier’s stock worth $159,747,000 after acquiring an additional 8,584 shares during the period. Vanguard Group Inc. raised its position in shares of LeMaitre Vascular by 0.3% in the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after acquiring an additional 4,964 shares during the period. Copeland Capital Management LLC raised its position in shares of LeMaitre Vascular by 2.3% in the fourth quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock worth $71,515,000 after acquiring an additional 28,720 shares during the period. Ranger Investment Management L.P. raised its position in shares of LeMaitre Vascular by 1.5% in the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after acquiring an additional 13,681 shares during the period. Finally, Congress Asset Management Co. MA raised its position in shares of LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after acquiring an additional 71,411 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.